Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: A randomized controlled trial

Addiction

Volumn 108, Issue 10, 2013, Pages 1836-1844

  King, Andrea ^a   Cao, Dingcai ^b   Zhang, Lingjiao ^a   Rueger, Sandra Yu ^a,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c WHEATON COLLEGE   (United States)

Author keywords

Alcohol; Cigarette smoking; Cotinine; Naltrexone; Opioid antagonist; Smoking urge

Indexed keywords

ALCOHOL; COTININE; NALTREXONE; NARCOTIC ANTAGONIST; OPIATE ANTAGONIST;

ADDICTION; ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; SMOKING URGE; TREATMENT OUTCOME; UNITED STATES; BEHAVIOR, ADDICTIVE; EPIDEMIOLOGY; PROCEDURES;

ALCOHOL; CIGARETTE SMOKING; COTININE; NALTREXONE; OPIOID ANTAGONIST; SMOKING URGE;

ADULT; ALCOHOL DRINKING; BEHAVIOR, ADDICTIVE; CHICAGO; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 84884209872     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12261     Document Type: Article

References (49)

1. Centers for Disease Control (CDC). Current cigarette smoking prevalence among working adults-United States, 2004-2010. Morb Mortal Wkly Rep 2011; 60: 1305-1309.
2. Centers for Disease Control (CDC). Quitting smoking among adults-United States, 2001-2010. Morb Mortal Wkly Rep 2011; 60: 1513-1519.
3. Fiore M. C., Jaén C. R., Baker T. B., Bailey W. C., Benowitz N. L., Curry S. J. etal. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services Public Health Service; 2008 May.
4. Pomerleau O. F. Endogenous opioids and smoking: a review of progress and problems. Psychoneuroendocrinology 1998; 23: 115-130.
5. Watkins S. S., Koob G. F., Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2000; 2: 19-37.
6. McKee S. A., Krishnan-Sarin S., Shi J., Mase T., O'Malley S. S. Modeling the effect of alcohol on smoking lapse behavior. Psychopharmacology (Berl) 2006; 189: 201-210.
7. Borland R. Slip-ups and relapse in attempts to quit smoking. Addict Behav 1990; 15: 235-245.
8. Shiffman S., Paty J. A., Gnys M., Kassel J. A., Hickcox M. First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 1996; 64: 366-379.
9. Shiffman S., Gwaltney C. J., Balabanis M. H., Liu K. S., Paty J. A., Kassel J. D. etal. Immediate antecedents of cigarette smoking: an analysis from ecological momentary assessment. J Abnorm Psychol 2002; 111: 531-545.
10. Byars J. A., Frost-Pineda K., Jacobs W. S., Gold M. S. Naltrexone augments the effects of nicotine replacement therapy in female smokers. J Addict Dis 2005; 24: 49-60.
11. Covey L. S., Glassman A. H., Stetner F. Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis 1999; 18: 31-40.
12. King A., de Wit H., Riley R. C., Cao D., Niaura R., Hatsukami D. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res 2006; 8: 671-682.
13. King A. C., Cao D., O'Malley S. S., Kranzler H. R., Cai X., Dewit H. etal. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol 2012; 32: 630-636.
14. O'Malley S. S., Cooney J. L., Krishnan-Sarin S., Dubin J. A., McKee S. A., Cooney N. L. etal. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med 2006; 166: 667-674.
15. Toll B. A., White M., Wu R., Meandzija B., Jatlow P., Makuch R. etal. Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial. Drug Alcohol Depend 2010; 111: 200-206.
16. Wong G. Y., Wolter T. D., Croghan G. A., Croghan I. T., Offord K. P., Hurt R. D. A randomized trial of naltrexone for smoking cessation. Addiction 1999; 94: 1227-1237.
17. King A. C., Cao D., Zhang L., O'Malley S. Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial. Biol Psychiatry 2013; 73: 924-930.
18. David S. P., Lancaster T., Stead L. F., Evins A. E., Prochaska J. J. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev 2013; 6:CD003086.
19. Epstein A. M., King A. C. Naltrexone attenuates acute cigarette smoking behavior. Pharmacol Biochem Behav 2004; 77: 29-37.
20. Hutchison K. E., Monti P. M., Rohsenow D. J., Swift R. M., Colby S. M., Gnys M. etal. Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology (Berl) 1999; 142: 139-143.
21. King A. C., Meyer P. J. Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav 2000; 66: 563-572.
22. Lee Y. S., Joe K. H., Sohn I. K., Na C., Kee B. S., Chae S. L. Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 639-647.
23. Wewers M. E., Dhatt R., Tejwani G. A. Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology (Berl) 1998; 140: 185-190.
24. Brauer L. H., Behm F. M., Westman E. C., Patel P., Rose J. E. Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology (Berl) 1999; 143: 339-346.
25. Rohsenow D. J., Monti P. M., Hutchison K. E., Swift R. M., MacKinnon S. V., Sirota A. D. etal. High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking. Exp Clin Psychopharmacol 2007; 15: 81-92.
26. Sutherland G., Stapleton J. A., Russell M. A., Feyerabend C. Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology (Berl) 1995; 120: 418-425.
27. Plebani J. G., Ray L. A., Morean M. E., Corbin W. R., Mackillop J., Amlung M. etal. Human laboratory paradigms in alcohol research. Alcohol Clin Exp Res 2012; 36: 972-983.
28. Davidson D., Swift R., Fitz E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 1996; 20: 732-739.
29. Anton R. F., Drobes D. J., Voronin K., Durazo-Avizu R., Moak D. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl) 2004; 173: 32-40.
30. Krishnan-Sarin S., Rosen M. I., O'Malley S. S. Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Arch Gen Psychiatry 1999; 56: 663-668.
31. Baron R. M., Kenny D. A. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986; 51: 1173-1182.
32. Schoenfeld D. A. Sample-size formula for the proportional-hazards regression model. Biometrics 1983; 39: 499-503.
33. Croop R. S., Faulkner E. B., Labriola D. F. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 1997; 54: 1130-1135.
34. Nehlig A., Daval J. L., Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 1992; 17: 139-170.
35. Kenny P. J. Common cellular and molecular mechanisms in obesity and drug addiction. Nat Rev Neurosci 2011; 12: 638-651.
36. Glass M. J., Billington C. J., Levine A. S. Opioids and food intake: distributed functional neural pathways? Neuropeptides 1999; 33: 360-368.
37. Pecina S., Smith K. S. Hedonic and motivational roles of opioids in food reward: implications for overeating disorders. Pharmacol Biochem Behav 2010; 97: 34-46.
38. Wong K. J., Wojnicki F. H., Corwin R. L. Baclofen, raclopride, and naltrexone differentially affect intake of fat/sucrose mixtures under limited access conditions. Pharmacol Biochem Behav 2009; 92: 528-536.
39. Yeomans M. R., Gray R. W. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 2002; 26: 713-728.
40. Kenny P. J. Reward mechanisms in obesity: new insights and future directions. Neuron 2011; 69: 664-679.
41. Robinson T. E., Berridge K. C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993; 18: 247-291.
42. Robinson T. E., Berridge K. C. Review. The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc Lond B Biol Sci 2008; 363: 3137-3146.
43. Higgins S. T., Heil S. H., Dumeer A. M., Thomas C. S., Solomon L. J., Bernstein I. M. Smoking status in the initial weeks of quitting as a predictor of smoking-cessation outcomes in pregnant women. Drug Alcohol Depend 2006; 85: 138-141.
44. Kenford S. L., Fiore M. C., Jorenby D. E., Smith S. S., Wetter D., Baker T. B. Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA 1994; 271: 589-594.
45. Hajek P., McRobbie H. J., Myers K. E., Stapleton J., Dhanji A. R. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch Intern Med 2011; 171: 770-777.
46. Oslin D. W., Berrettini W. H., O'Brien C. P. Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. Addict Biol 2006; 11: 397-403.
47. King A., Cao D., Vanier C., Wilcox T. Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study. Alcohol Clin Exp Res 2009; 33: 1044-1050.
48. O'Malley S. S., Krishnan-Sarin S., McKee S. A., Leeman R. F., Cooney N. L., Meandzija B. etal. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. Int J Neuropsychopharmacol 2009; 12: 589-597.
49. Fucito L. M., Park A., Gulliver S. B., Mattson M. E., Gueorguieva R. V., O'Malley S. S. Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. Biol Psychiatry 2012; 72: 832-838.